BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Sritharan S, Sivalingam N. A comprehensive review on time-tested anticancer drug doxorubicin. Life Sci 2021;278:119527. [PMID: 33887349 DOI: 10.1016/j.lfs.2021.119527] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Farag MR, Moselhy AAA, El-Mleeh A, Aljuaydi SH, Ismail TA, Di Cerbo A, Crescenzo G, Abou-Zeid SM. Quercetin Alleviates the Immunotoxic Impact Mediated by Oxidative Stress and Inflammation Induced by Doxorubicin Exposure in Rats. Antioxidants (Basel) 2021;10:1906. [PMID: 34943009 DOI: 10.3390/antiox10121906] [Reference Citation Analysis]
2 Gao H, Xian G, Zhong G, Huang B, Liang S, Zeng Q, Liu Y. Alleviation of doxorubicin-induced cardiomyocyte death through miR-147-y-mediated mitophagy. Biochem Biophys Res Commun 2022;609:176-82. [PMID: 35452958 DOI: 10.1016/j.bbrc.2022.04.013] [Reference Citation Analysis]
3 Uprety B, Chandran R, Arderne C, Abrahamse H. Anticancer Activity of Urease Mimetic Cobalt (III) Complexes on A549-Lung Cancer Cells: Targeting the Acidic Microenvironment. Pharmaceutics 2022;14:211. [DOI: 10.3390/pharmaceutics14010211] [Reference Citation Analysis]
4 Fontana F, Limonta P. The multifaceted roles of mitochondria at the crossroads of cell life and death in cancer. Free Radic Biol Med 2021;176:203-21. [PMID: 34597798 DOI: 10.1016/j.freeradbiomed.2021.09.024] [Reference Citation Analysis]
5 Roque MC, da Silva CD, Lempek MR, Cassali GD, de Barros ALB, Melo MM, Oliveira MC. Preclinical toxicological study of long-circulating and fusogenic liposomes co-encapsulating paclitaxel and doxorubicin in synergic ratio. Biomed Pharmacother 2021;144:112307. [PMID: 34653762 DOI: 10.1016/j.biopha.2021.112307] [Reference Citation Analysis]
6 Sacks B, Onal H, Martorana R, Sehgal A, Harvey A, Wastella C, Ahmad H, Ross E, Pjetergjoka A, Prasad S, Barsotti R, Young LH, Chen Q. Mitochondrial targeted antioxidants, mitoquinone and SKQ1, not vitamin C, mitigate doxorubicin-induced damage in H9c2 myoblast: pretreatment vs. co-treatment. BMC Pharmacol Toxicol 2021;22:49. [PMID: 34530934 DOI: 10.1186/s40360-021-00518-6] [Reference Citation Analysis]
7 Liu J, Xin Y, Qiu Z, Zhang Q, He T, Qiu Y, Wang W. Cordyceps sinensis -mediated biotransformation of notoginsenoside R1 into 25-OH-20( S / R )-R2 with elevated cardioprotective effect against DOX-induced cell injury. RSC Adv 2022;12:12938-46. [DOI: 10.1039/d2ra01470j] [Reference Citation Analysis]
8 Xu ST, Yang C, Yan XP. Nanothorn Filter-Facilitated Online Cell Lysis for Rapid and Deep Intracellular Profiling by Single-Cell Mass Spectrometry. Anal Chem 2021;93:15677-86. [PMID: 34784185 DOI: 10.1021/acs.analchem.1c03529] [Reference Citation Analysis]
9 Loissell-Baltazar YA, Dokudovskaya S. SEA and GATOR 10 Years Later. Cells 2021;10:2689. [PMID: 34685669 DOI: 10.3390/cells10102689] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Kovrigina E, Chubarov A, Dmitrienko E. High Drug Capacity Doxorubicin-Loaded Iron Oxide Nanocomposites for Cancer Therapy. Magnetochemistry 2022;8:54. [DOI: 10.3390/magnetochemistry8050054] [Reference Citation Analysis]
11 Shirai Y, Chow CCT, Kambe G, Suwa T, Kobayashi M, Takahashi I, Harada H, Nam JM. An Overview of the Recent Development of Anticancer Agents Targeting the HIF-1 Transcription Factor. Cancers (Basel) 2021;13:2813. [PMID: 34200019 DOI: 10.3390/cancers13112813] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
12 Pho C, Frieler M, Akkaraju GR, Naumov AV, Dobrovolny HM. Using mathematical modeling to estimate time-independent cancer chemotherapy efficacy parameters. In Silico Pharmacol 2022;10:2. [PMID: 34926126 DOI: 10.1007/s40203-021-00117-7] [Reference Citation Analysis]
13 Hu Q, Yammani RD, Brown-harding H, Soto-pantoja DR, Poole LB, Lukesh JC. Mitigation of doxorubicin-induced cardiotoxicity with an H2O2-Activated, H2S-Donating hybrid prodrug. Redox Biology 2022;53:102338. [DOI: 10.1016/j.redox.2022.102338] [Reference Citation Analysis]
14 Wang D, Bao H. Abemaciclib is synergistic with doxorubicin in osteosarcoma pre-clinical models via inhibition of CDK4/6-Cyclin D-Rb pathway. Cancer Chemother Pharmacol 2021. [PMID: 34655298 DOI: 10.1007/s00280-021-04363-6] [Reference Citation Analysis]
15 Salzillo A, Ragone A, Spina A, Naviglio S, Sapio L. Chlorogenic Acid Enhances Doxorubicin-Mediated Cytotoxic Effect in Osteosarcoma Cells. Int J Mol Sci 2021;22:8586. [PMID: 34445291 DOI: 10.3390/ijms22168586] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Blöchl C, Wang D, Madunić K, Lageveen-Kammeijer GSM, Huber CG, Wuhrer M, Zhang T. Integrated N- and O-Glycomics of Acute Myeloid Leukemia (AML) Cell Lines. Cells 2021;10:3058. [PMID: 34831278 DOI: 10.3390/cells10113058] [Reference Citation Analysis]
17 Hou J, Yun Y, Cui C, Kim S. Ginsenoside Rh2 mitigates doxorubicin-induced cardiotoxicity by inhibiting apoptotic and inflammatory damage and weakening pathological remodelling in breast cancer-bearing mice. Cell Prolif 2022;:e13246. [PMID: 35534947 DOI: 10.1111/cpr.13246] [Reference Citation Analysis]
18 Forma E, Bryś M. Anticancer Activity of Propolis and Its Compounds. Nutrients 2021;13:2594. [PMID: 34444754 DOI: 10.3390/nu13082594] [Reference Citation Analysis]